Relief/NeuroRx's RLF-100 results in 72% survival in COVID-19 under EAP

 

• Relief Therapeutics (OTCQB:RLFTF) and NeuroRx announce that more than 175 patients with Critical COVID-19 and Respiratory Failure have now been entered into an Expanded Access Protocol (EAP) with RLF-100 in the U.S.
• All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing Phase 2b/3 trial for COVID-19.
• Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.
• As previously reported, 21 RLF-100 treated patients when compared to 24 control patients, only 17% of the control group survived to day 28.
• The survival rate with RLF-100 reported today is comparable to that of the open-label patients treated with RLF-100 by Youssef et al.
• No drug-related serious adverse events have been reported in either EAP or Phase 2b/3 U.S. trial currently underway.
• Currently, 25 U.S. hospitals have enrolled patients in the EAP, suggesting that RLF-100 can demonstrate effectiveness.
• Physicians enrolling patients in the EAP have reported that initial patients at their sites have frequently been in ICU for several weeks without recovery prior to treatment with RLF-100.
• https://seekingalpha.com/news/3638922-relief-neurorxs-rlfminus-100-results-in-72-survival-of-covidminus-19-patients-under-eap